Skip to main content
Top
Published in: BMC Public Health 1/2006

Open Access 01-12-2006 | Research article

Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison

Authors: Andrew J Sutton, W John Edmunds, O Noel Gill

Published in: BMC Public Health | Issue 1/2006

Login to get access

Abstract

Background

In England and Wales where less than 1% of the population are Injecting drug users (IDUs), 97% of HCV reports are attributed to injecting drug use. As over 60% of the IDU population will have been imprisoned by the age of 30 years, prison may provide a good location in which to offer HCV screening and treatment. The aim of this work is to examine the cost effectiveness of a number of alternative HCV case-finding strategies on prison reception

Methods

A decision analysis model embedded in a model of the flow of IDUs through prison was used to estimate the cost effectiveness of a number of alternative case-finding strategies. The model estimates the average cost of identifying a new case of HCV from the perspective of the health care provider and how these estimates may evolve over time.

Results

The results suggest that administering verbal screening for a past positive HCV test and for ever having engaged in illicit drug use prior to the administering of ELISA and PCR tests can have a significant impact on the cost effectiveness of HCV case-finding strategies on prison reception; the discounted cost in 2017 being £2,102 per new HCV case detected compared to £3,107 when no verbal screening is employed.

Conclusion

The work here demonstrates the importance of targeting those individuals that have ever engaged in illicit drug use for HCV testing in prisons, these individuals can then be targeted for future intervention measures such as treatment or monitored to prevent future transmission.
Appendix
Available only for authorised users
Literature
1.
go back to reference Limburg W: Hepatitis C and injecting drug use: impact, costs and policy options. Edited by: Jager J, Limburg W, Kretzschmar M, Postma M and Wiessing L. 2004, Lisbon, European Monitoring Centre for Drugs and Drug Addiction, 21-38. Natural history, treatment and prevention of hepatitis C in injecting drug users; an overview, EMCDDA Monographs. Limburg W: Hepatitis C and injecting drug use: impact, costs and policy options. Edited by: Jager J, Limburg W, Kretzschmar M, Postma M and Wiessing L. 2004, Lisbon, European Monitoring Centre for Drugs and Drug Addiction, 21-38. Natural history, treatment and prevention of hepatitis C in injecting drug users; an overview, EMCDDA Monographs.
3.
go back to reference Leal P, Stein K, Rosenberg W: What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?. J Med Screen. 1999, 6: 124-131.CrossRefPubMed Leal P, Stein K, Rosenberg W: What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users?. J Med Screen. 1999, 6: 124-131.CrossRefPubMed
4.
go back to reference Agency HP, Scotland HP, National Public Health Service for Wales, Ireland CDSCN, CRDHB, UASSG: Shooting Up; Infections among injecting drug users in the United Kingdom 2004, An update: October 2005. 2005, London, Health Protection Agency Agency HP, Scotland HP, National Public Health Service for Wales, Ireland CDSCN, CRDHB, UASSG: Shooting Up; Infections among injecting drug users in the United Kingdom 2004, An update: October 2005. 2005, London, Health Protection Agency
5.
go back to reference Weissing L, Roy K, Sapinho D, Hay G, Taylor A, Goldberg D, Hartnoll R: Hepatitis C and injecting drug use: impact, costs and policy options. Edited by: Jager J, Limburg W, Kretzschmar M, Postma M and Wiessing L. 2006, Luxembourg, European Monitoring Centre for Drugs and Drug Addiction, 91-135. Surveillance of hepatitis C infection among injecting drug users in the European Union, EMCDDA Monographs. Weissing L, Roy K, Sapinho D, Hay G, Taylor A, Goldberg D, Hartnoll R: Hepatitis C and injecting drug use: impact, costs and policy options. Edited by: Jager J, Limburg W, Kretzschmar M, Postma M and Wiessing L. 2006, Luxembourg, European Monitoring Centre for Drugs and Drug Addiction, 91-135. Surveillance of hepatitis C infection among injecting drug users in the European Union, EMCDDA Monographs.
6.
go back to reference Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L: Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect. 2002, 129: 577-585. 10.1017/S0950268802007902.CrossRefPubMedPubMedCentral Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L: Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect. 2002, 129: 577-585. 10.1017/S0950268802007902.CrossRefPubMedPubMedCentral
7.
go back to reference de Angelis D, Hickman M, Yang S: Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am J Epidemiol. 2004, 160: 994-1004. 10.1093/aje/kwh306.CrossRefPubMed de Angelis D, Hickman M, Yang S: Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am J Epidemiol. 2004, 160: 994-1004. 10.1093/aje/kwh306.CrossRefPubMed
8.
go back to reference Frischer M, Hickman M, Kraus L, Mariani F, Wiessing L: A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain. Addiction. 2001, 96: 1465-1476. 10.1046/j.1360-0443.2001.9610146510.x.CrossRefPubMed Frischer M, Hickman M, Kraus L, Mariani F, Wiessing L: A comparison of different methods for estimating the prevalence of problematic drug misuse in Great Britain. Addiction. 2001, 96: 1465-1476. 10.1046/j.1360-0443.2001.9610146510.x.CrossRefPubMed
9.
go back to reference Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM: Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut. 2003, 52: 1500-1504. 10.1136/gut.52.10.1500.CrossRefPubMedPubMedCentral Skipper C, Guy JM, Parkes J, Roderick P, Rosenberg WM: Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy. Gut. 2003, 52: 1500-1504. 10.1136/gut.52.10.1500.CrossRefPubMedPubMedCentral
10.
go back to reference Schlicting EG, Johnson ME, Brems C, Wells RS, Fisher DG, Reynolds G: Validity of injecting drug users' self report of hepatitis A, B, and C. Clin Lab Sci. 2003, 16: 99-106.PubMed Schlicting EG, Johnson ME, Brems C, Wells RS, Fisher DG, Reynolds G: Validity of injecting drug users' self report of hepatitis A, B, and C. Clin Lab Sci. 2003, 16: 99-106.PubMed
11.
go back to reference Reuter P: What drug policies cost: estimating government drug policy expenditures. Addiction. 2006, 101: 315-322. 10.1111/j.1360-0443.2005.01336.x.CrossRefPubMed Reuter P: What drug policies cost: estimating government drug policy expenditures. Addiction. 2006, 101: 315-322. 10.1111/j.1360-0443.2005.01336.x.CrossRefPubMed
12.
go back to reference Sutton AJ, Gay NJ, Edmunds WJ, Andrews NJ, Hope VD, Gilbert RL, Piper M, Gill ON: Modelling the hepatitis B vaccination programme in prisons. Epidemiol Infect. 2006, 134: 231-242. 10.1017/S0950268805005182.CrossRefPubMed Sutton AJ, Gay NJ, Edmunds WJ, Andrews NJ, Hope VD, Gilbert RL, Piper M, Gill ON: Modelling the hepatitis B vaccination programme in prisons. Epidemiol Infect. 2006, 134: 231-242. 10.1017/S0950268805005182.CrossRefPubMed
13.
go back to reference Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M: Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis. 2006, 6: 93-10.1186/1471-2334-6-93.CrossRefPubMedPubMedCentral Sutton AJ, Gay NJ, Edmunds WJ, Hope VD, Gill ON, Hickman M: Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis. 2006, 6: 93-10.1186/1471-2334-6-93.CrossRefPubMedPubMedCentral
14.
go back to reference Macalino GE, Hou JC, Kumar MS, Taylor LE, Sumantera IG, Rich JD: Hepatitis C infection and incarcerated populations. The International Journal of Drug Policy. 2004, 151: 103-114. 10.1016/j.drugpo.2003.10.006.CrossRef Macalino GE, Hou JC, Kumar MS, Taylor LE, Sumantera IG, Rich JD: Hepatitis C infection and incarcerated populations. The International Journal of Drug Policy. 2004, 151: 103-114. 10.1016/j.drugpo.2003.10.006.CrossRef
15.
go back to reference Health Protection Agency Centre for Infections: Hepatitis C in England: The First Health Protection Agency Annual Report. 2005, London Health Protection Agency Centre for Infections: Hepatitis C in England: The First Health Protection Agency Annual Report. 2005, London
16.
go back to reference Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J: Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. BMJ. 1999, 319: 290-291.CrossRefPubMedPubMedCentral Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J: Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. BMJ. 1999, 319: 290-291.CrossRefPubMedPubMedCentral
17.
go back to reference Darke S: Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998, 51: 253-263. 10.1016/S0376-8716(98)00028-3.CrossRefPubMed Darke S: Self-report among injecting drug users: a review. Drug Alcohol Depend. 1998, 51: 253-263. 10.1016/S0376-8716(98)00028-3.CrossRefPubMed
18.
go back to reference Treasury HM: The Green Book, Apprasial and Evaluation in Central Government. 2003 Treasury HM: The Green Book, Apprasial and Evaluation in Central Government. 2003
19.
go back to reference Mortimer P: Ready, steady, go for HCV antigen testing?. Commun Dis Public Health. 2000, 3: 154-155.PubMed Mortimer P: Ready, steady, go for HCV antigen testing?. Commun Dis Public Health. 2000, 3: 154-155.PubMed
20.
go back to reference Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998, 47: 1-39. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998, 47: 1-39.
21.
go back to reference Horne JA, Clements AJ, Drennan P, Stein K, Cramp ME: Screening for hepatitis C virus in the Dartmoor prison population: an observational study. J Public Health (Oxf). 2004, 26: 372-375. 10.1093/pubmed/fdh174.CrossRef Horne JA, Clements AJ, Drennan P, Stein K, Cramp ME: Screening for hepatitis C virus in the Dartmoor prison population: an observational study. J Public Health (Oxf). 2004, 26: 372-375. 10.1093/pubmed/fdh174.CrossRef
22.
go back to reference 2000, National Institute for Clinical Excellence, 14: Guidance on the use of Ribavirin and Interferon Alpha for Hepatitis C, Technology Appraisal Guidance. 2000, National Institute for Clinical Excellence, 14: Guidance on the use of Ribavirin and Interferon Alpha for Hepatitis C, Technology Appraisal Guidance.
23.
go back to reference Curtis L, Netten A: Unit Costs of Health and Social Care. 2004, Personal Social Services Research Unit Curtis L, Netten A: Unit Costs of Health and Social Care. 2004, Personal Social Services Research Unit
24.
go back to reference Stein K, Dalziel K, Walker A, McIntyre L, Jenkins B, Horne J, Royle P, Round A: Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess. 2002, 6 (31): 1-122. Stein K, Dalziel K, Walker A, McIntyre L, Jenkins B, Horne J, Royle P, Round A: Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice. Health Technol Assess. 2002, 6 (31): 1-122.
26.
go back to reference Seeff LB: Natural history of chronic hepatitis C. Hepatology. 2002, 36: S35-S46. 10.1002/hep.1840360706.CrossRefPubMed Seeff LB: Natural history of chronic hepatitis C. Hepatology. 2002, 36: S35-S46. 10.1002/hep.1840360706.CrossRefPubMed
Metadata
Title
Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison
Authors
Andrew J Sutton
W John Edmunds
O Noel Gill
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2006
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-6-170

Other articles of this Issue 1/2006

BMC Public Health 1/2006 Go to the issue